• Explore /
  • Poster
  • / BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC).

BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC).

Abstract Poster

Authors

null

B. Melichar

Department of Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

B. Melichar , S. Bracarda , V. Matveev , I. Rusakov , A. Kaprin , A. Zyryanov , R. Janciauskiene , E. Fernebro , G. H. Mickisch , M. E. Gore , A. Schulze , S. Jethwa , V. Sneller , P. Mulders , J. Bellmunt

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT00796757

Citation

J Clin Oncol 29: 2011 (suppl; abstr 4546)

Abstract #

4546

Poster Bd #

1

Abstract Disclosures

Similar Posters

First Author: Hideaki Bando

First Author: Jin Yan

First Author: Martin Boegemann

First Author: Martin Schostak